Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Beta3-Integrin Protein Possible Key to Block Tumor Growth

By BiotechDaily International staff writers
Posted on 15 Jan 2014
Image: Graphic of Cytoplasmic domain of the integrin beta-3 (Photo courtesy of Wikipedia Commons).
Image: Graphic of Cytoplasmic domain of the integrin beta-3 (Photo courtesy of Wikipedia Commons).
A protein that has been at the forefront of cancer drug development for the last 20 years should not be given up on according to new findings by British investigators.

The most advanced version of αvβ3-integrin antagonists was unsuccessful in clinical trials to treat aggressive forms of brain cancer. However, research published January 3, 2014, in the American Heart Association’s journal Circulation Research revealed that targeting the specific protein could still be key to blocking tumor growth. Most significantly, the drugs targeting the protein cause minimal side effects compared to other drugs, which can cause high blood pressure and bleeding in the gut.

Tumors must recruit their own blood supply to grow beyond a very small size. The researchers examined the cells that line blood vessels (endothelial cells) in mice, and specifically the role of a widely expressed protein called beta3-integrin.

Dr. Stephen Robinson, from the University of East Anglia’s (UEA; Norwich, UK) School of Biological Sciences, said, “This protein has been the focus of drug design over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment. The most advanced of these drugs, however, has recently failed a phase III clinical trial to treat an aggressive form of brain cancer. In line with other clinical work, patients respond to treatment for a short while but then their cancers escape the treatment. This research helps to explain why these very promising drugs aren’t meeting with the success that was anticipated and it suggests a way forward—how to make them work better.”

The study authors additionally reported that they revealed how tumors continue to grow in spite of treatment that should suppress blood vessel recruitment. In this study, they modulated how they are recruiting their blood vessels by using a different pathway from the one that is being targeted. They have identified some molecular alterations in endothelial cells that occur with long-term suppression of beta3-integrin that might help the cells evade the beta3-integrin blockade.

Dr. Robinson continued, “Our research also shows that timing is critical when targeting the protein beta3-integrin. Importantly, these findings have reestablished the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be refocused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist.”

Related Links:

University of East Anglia



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.